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PCV9
OUTCOMES AND COSTS OF
THROMBOPROPHYLAXIS WITH LOW-
MOLECULAR WEIGHT HEPARIN IN ACUTELY-
ILL MEDICAL INPATIENTS
Thompson D, McGarry L
Innovus Research, Inc, Medford, MA, USA
OBJECTIVE: Prophylactic administration of low-
molecular weight heparin (LMWH) has been shown to
reduce the occurrence of venous thromboembolism 
(VTE) among acutely-ill medical patients in the clinical
trial setting. The purpose of this study was to examine
outcomes and costs of LMWH thromboprophylaxis
among medical inpatients in real-world clinical practice.
METHODS: Using a large, geographically-diverse, multi-
hospital U.S. database, we identiﬁed persons aged ≥40
years who were hospitalized for ≥6 days with an acute
medical condition (including circulatory disorders, respi-
ratory disorders, infectious diseases, or neoplasms) during
calendar year 2000. From these patients we identiﬁed
those who received either thromboprophylaxis with the
LMWH enoxaparin or no thromboprophylaxis. Surgical
patients, patients with conditions requiring anticoagulant
therapy, and those medically ineligible for anticoagula-
tion were excluded. We compared the incidence of VTE
(deﬁned as deep-vein thrombosis [DVT] or pulmonary
embolism [PE]) and death during the hospital stay, as well
as length of inpatient stay and total costs, in the two
cohorts. RESULTS: We identiﬁed 215 patients receiving
enoxaparin prophylaxis and 3595 receiving no prophy-
laxis. The risk of VTE over the course of the hospitaliza-
tion was 58% lower with enoxaparin prophylaxis than
with no prophylaxis (3.3% versus 7.9%; p < 0.001); there
was no difference in the risk of death (7.4% versus 7.3%;
p = 0.96). Length of stay in hospital and costs of inpa-
tient stay were nominally higher in the group receiving
enoxaparin prophylaxis versus no prophylaxis (10.4 days
versus 10.1 days; US$10,497 versus US$9,904), although
the magnitude of these differences was not signiﬁcant 
(p = 0.40 for length of stay; p = 0.29 for costs). CON-
CLUSIONS: Prophylaxis with LMWH was found to be
effective in reducing the risk of thromboembolism in
medical inpatients in real-world clinical practice;
however, no corresponding reductions in length of hos-
pital stay and inpatient costs were observed.
PCV10
COST OF UNCONTROLLED HYPERTENSION 
IN CANADA
Ali F1, Scott DA2, Lloyd A2, Feldman RD3
1Pﬁzer Canada Inc, Kirkland, QC, Canada; 2Fourth Hurdle
Consulting, London, United Kingdom; 3Robarts Research
Institute, London, ON, Canada
OBJECTIVES: To estimate the avoidable health care
costs of uncontrolled hypertension in Canada.
METHODS: We used an established cost of illness model
to estimate cost of cardiovascular (CV) hospitalisations
at current prevalence of hypertension to the Canadian
health care system, and the level of these costs if hyper-
tension was successfully treated to target levels. Two 
populations were examined: hypertensives in the general
population; and a subpopulation with both hypertension
and Non-Insulin Dependent Diabetes Mellitus (NIDDM).
Population data were sourced from the 2001 census.
Prevalence of hypertension in the general population 
was taken from the Canadian Heart Health Survey and
in NIDDM was calculated from Diabetes in Canada 
and Canadian Diabetes Association data. The HOT trial
and Framingham Risk Proﬁle equation were used to
examine the relationship between achieved blood pres-
sure and 3 major CV events—stroke, congestive heart
failure (CHF), and symptomatic acute myocardial infarc-
tion (AMI). Cost of CV events were taken from the
Ontario Case Costing Project (AMI and CHF) and the
Canadian Economic Burden of Illness Study (stroke). Sto-
chastic simulation was used to construct conﬁdence inter-
vals. RESULTS: The model estimated that 5.3 million 
Canadians over age 18 have hypertension. Uncontrolled
hypertension was associated with 17,000 excess CV
events and costs of C$306 million (95%CI: C$154–
632m) annually. Among 309,000 hypertensives with
NIDDM, uncontrolled hypertension was associated with
4,000 excess CV events annually and costs of C$68
million (95%CI: C$37–103m). CONCLUSIONS:
Uncontrolled hypertension contributes substantially to
the overall cost of cardiovascular disease in Canada. Dia-
betic hypertensives represented 22% of the avoidable cost
of hypertension and 6% of the hypertensives population.
PCV11
RESOURCE UTILIZATION DURING THE FOUR
MONTHS FOLLOWING A DIAGNOSIS OF DEEP
VENOUS THROMBOSIS
Kahn SR1, Ducruet T1, Johri M2,Arsenault L1,
Venous Thrombosis Outcomes (VETO) Study Investigators3
1McGill University, Montreal, QC, Canada; 2Université de
Montréal, Montreal, QC, Canada; 3McGill University, Université
de Montréal, Université de Laval, Montreal, QC, Canada
OBJECTIVES: Deep venous thrombosis (DVT) is a
common cardiovascular condition occurring in 2 per
1000 persons/year. Despite its frequency, the economic
impact of DVT has not been quantiﬁed. During a
prospective Canadian multicenter study of longterm out-
comes after DVT, we quantiﬁed DVT-related resource 
utilization during the four months following diagnosis.
METHODS: The study population consisted of 153
patients diagnosed with acute DVT at 1 of 7 participat-
ing hospitals. Data on DVT-related hospitalisations,
physician visits, diagnostic tests, medical devices, para-
medical services and indirect costs were collected for 
the 4-month period following diagnosis. Data sources
included weekly patient-completed diaries, nurse-
completed case report forms (baseline, 1, 4 months, and
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at any potential DVT-related clinical event [DRCE]), and
archivist-coded hospitalisation summaries. Utilization
was grouped by resource-type and summed. Stratiﬁed
analyses were performed by age, gender, DVT site (prox-
imal/distal), and patient location (in-patient/out-patient).
RESULTS: At diagnosis, mean age was 57 years, 48%
were male, 1/3 were in-patients and 55% had proximal
DVT. By 4 months, 17% of patients had ≥1 new hospi-
talisation, 24% had been investigated for a DRCE and
there were a mean of 0.9 emergency department visits,
3.4 family physician visits, 5.2 specialist physician visits
and 13.4 episodes of use of paramedical services. Half 
of patients had purchased elastic stockings, and 69%
were still taking warfarin. By 1 month, 31% and 17% of
patients reported cutting down on household and work
activities, respectively; at 4 months, these ﬁgures were
15% and 7%. There was an average loss of 7.3 work-
days during the 4-month period. CONCLUSIONS:
Although usually considered an acute condition, DVT 
is associated with signiﬁcant utilization of resources and
loss of productivity for at least 4 months after diagnosis.
The longterm economic impact of DVT should be further
quantiﬁed and factored into cost-effectiveness studies of
strategies to prevent or treat DVT.
PCV12
COST-EFFECTIVENES OF ENOXAPARIN AS
THROMBOPROPHYLAXIS IN ACUTELY ILL
MEDICAL PATIENTS IN BRAZIL
Nuijten MJC1, Mussi N2, Kosa J1, Ramacciotti E1,
Glancspiegel D1, Nadipelli V2
1MEDTAP International, Jisp, Netherlands; 2Aventis
Pharmaceuticals, Inc, Bridgewater, NJ, USA;
OBJECTIVE: To generate estimates of the cost-
effectiveness of thromboprophylaxis with enoxaparin
versus no thromboprophylaxis (usual care) in patients
with acute medical illness in the health care setting of
Brazil from the perspective of the public Brazilian health
care system. METHODS: Markov process analysis tech-
niques were used to model the health economic outcomes.
Data on probabilities of clinical events were derived from
clinical trial data from the MEDENOX trial, other pub-
lished literature and OECD (Organisation for Economic
Co-Operation and Development) country-speciﬁc popu-
lation mortality data; units of health care utilization were
derived from the Delphi panels; prices and tariffs were
derived from ofﬁcial lists. RESULTS: Analysis over a 1-
year period showed that the cost per VTE event avoided
was REAL 2349 (US$870; €906) and the cost per life
saved was REAL 8296 (US$3073; €3201), when assum-
ing no higher risk for morbidity and mortality for asymp-
tomatic patients. The lifetime model (again, assuming 
no higher risk for recurrence of VTE for asymptomatic
patients), showed that the use of enoxaparin leads to a
cost per VTE event avoided of REAL 2194 (US$813;
€846) and cost per life year gained of REAL 574
(US$213; €221). The lifetime model, which assumes a
higher risk of VTE recurrence in asymptomatic patients,
leads to a cost of REAL 317 (US$117; €122) per VTE
event avoided and REAL 90 (US$33; €35) per life year
gained. CONCLUSION: The results showed that the
favourable clinical beneﬁt of enoxaparin results in posi-
tive short and long-term health economic beneﬁts.
PCV13
COST OF MANAGING UNSTABLE ANGINA
PATIENTS OVER A NINE-MONTH PERIOD:A
EUROPEAN APPROACH
Gabriel S, Spiesser J, Jourdan S, Carita P
Sanoﬁ-Synthelabo, Bagneux, France
OBJECTIVES: While the cost of managing patients with
myocardial infarction has been extensively studied, 
few data are available on the cost of managing unstable
angina (UA) patients. The aim of the study was to assess
the cost of UA patients in six European countries (France,
Belgium, Italy, Spain, Sweden, UK). METHODS: A
cohort simulation model was used. Patients entered the
model when hospitalised for UA. Resources use during
initial hospitalisation (length of stay, invasive procedures)
was extracted from a prospective database. The frequency
and type of following rehospitalisations for cardiovascu-
lar events were derived from a recent clinical trial. The
time horizon was nine months and the perspective was
that of the health care system. The hospital costs used for
each country were based on the local DRG system. Ofﬁ-
cial costs of outpatient medications were used. All costs
are expressed for year 2001. RESULTS: The global cost
of managing UA patients over a nine-month period was
divided in three parts: cost of initial hospitalisation, cost
of subsequent hospitalisations and cost of medications.
Total length of stay of initial hospitalisation ranges from
7.2 days in Sweden to 10.8 days in Spain. The number of
days in intensive care unit ranges from 1.6 in UK to 3.8
in Italy. In France, the global cost was estimated at €7471
per patient, breakdown of cost was as follows: initial hos-
pitalisation (57%), subsequent hospitalisations (33%),
medications (10%). For other countries, the global cost
per patient was as follows: Belgium €6987, UK £3083,
Italy €6908, Spain €6633, Sweden SEK 57608, with a
consistent breakdown across countries. CONCLUSION:
First hospitalisation is the main cost driver. Nevertheless
the cost of subsequent hospitalisations accounts for about
one third of the total cost highlighting the need for pre-
ventive treatment of subsequent cardiovascular events in
UA patients.
